Antibodies against different biomarkers have been widely used for the diagnosis and prognosis of various diseases. By combining advanced technologies and long-term scientific expertise in the field of antibody discovery, Creative Biolabs has achieved great success in the development of in vitro diagnostic (IVD) antibodies against diversified cancer biomarkers. Particularly, we offer high-quality IVD antibody development services targeting multiple myeloma SET domain (MMSET).
The Overview of Multiple Myeloma SET Domain (MMSET)
Multiple myeloma SET domain (MMSET), also known as WHSC1/NSD2, belongs to a family of nuclear receptor binding SET domain (NSD) proteins. Located at chromosome 4p16.3, MMSET gene undergoes alternative splicing and results in several protein isoforms: MMSET type I, MMSET type II and RE-IIBP. In addition to the SET domain, MMSET also contains other conserved domains including plant homeodomain (PHD) zinc fingers, a high mobility group box (HMG) domain and proline-tryptophane-rich (PWWP) domains, found in proteins with DNA and chromatin binding activities. The study of chromosomal translocations, generated by either aberrant CSR or VDJ rearrangement shows that MMSET domain is placed under the control of the strong enhancers of the lg loci, leading to the deregulation independently from the mechanism of IgH rearrangement.
Fig. 1 Representative immunohistochemical staining for MMSET expression in ovarian specimens and fallopian tube specimens.
MMSET Marker of Tumor Cells
MMSET is known to have histone methyltransferase activity and is deregulated early on in myeloma genesis. Overexpression of MMSET leads to global changes in histone methylation and it further promotes cell survival, progression, and DNA repair. MMSET expression is frequently detected in many different cancers in comparison to the corresponding normal tissues and in some carcinomas high MMSET protein expression correlates with tumor aggressiveness. In t(4;14) myeloma plasma cells, a number of studies have shown that suppression of MMSET expression affected cell proliferation by both decreasing cell viability and cell cycle progression, and also dysregulation of MMSET affects the expression of several genes involved in the regulation of cell-cycle progression, cell adhesion, and survival. Moreover, MMSET is overexpressed in solid tumors, particularly in breast cancer, myeloma, and glioblastoma, resulting in an aberrantly high global level of H3K36me2, a protein responsible for double-stranded DNA repair. Overexpression of MMSET in prostate cancer causes aberrations in gene transcription leading to a metastatic phenotype. Taken together, MMSET emerges as a potential target for therapeutic interventions against many types of tumors.
Fig. 2 Multiple myeloma ontogeny’s hypothesis.
IVD antibodies are extensively used in immunodiagnostic kits for disease screening, prognosis, and therapeutic monitoring. Through our role as a leading antibody service provider, Creative Biolabs is well-positioned to develop novel MMSET-specific antibodies for diagnostic uses. With our versatile IVD platform, we also offer immunoassay development services from scratch to commercial IVD kits. We can start with antigen sequences or available antibody pairs.
For more detailed information, please feel free to contact us or directly send us an inquiry.
For Research Use Only.
